Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.
Publication/Presentation Date
2-26-1993
Abstract
Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 or 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases.
Volume
259
Issue
5099
First Page
1321
Last Page
1324
ISSN
0036-8075
Published In/Presented At
Weiner, H. L., Mackin, G. A., Matsui, M., Orav, E. J., Khoury, S. J., Dawson, D. M., & Hafler, D. A. (1993). Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (New York, N.Y.), 259(5099), 1321–1324. https://doi.org/10.1126/science.7680493
Disciplines
Medicine and Health Sciences
PubMedID
7680493
Department(s)
Department of Medicine
Document Type
Article